This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Lyric Dinner Theater (B)
Hamermesh, Richard G.; Sharpe, James M.Case HBS-813044-EEntrepreneurshipSupplements the (A) Case. Rivka Belzer reflects on the results and actions taken during the 12 months following her first 6 months on the job. Supplements the (A) Case. Rivka Belzer took a job in her family owned business and worked diligently during the first 6 months to turn the business around. This supplemental case outlines a series of decisions she made after those 6 months and reports the financial results one year later.Starting at €5.74
-
Lyric Dinner Theater (A)
Hamermesh, Richard G.; Sharpe, James M.Case HBS-813043-EEntrepreneurshipLooking back at 5 years of losses, Rivka Belzer, a newly minted MBA, steps into her family owned business with their mandate to turn it around or close it. In her first 6 months, she has made a number of changes, with mixed results, but is beginning to show a profit. Many strategic, organizational, marketing, control and operational decisions lie ahead as she plans for the next year and tries to manage a difficult Board of Directors in the challe...Starting at €8.20
-
Lyric Dinner Theater (B) (Spanish version)
Hamermesh, Richard G.; Sharpe, James M.Case HBS-815S17EntrepreneurshipSuplementos el caso (A). Rivka Belzer refleja en los resultados y las medidas adoptadas durante los 12 meses siguientes a su primer 6 meses en el trabajo. Suplementos el caso (A). Rivka Belzer tomó un trabajo en su empresa familiar y trabajó diligentemente durante los primeros 6 meses para convertir el negocio alrededor. Este caso suplementario esboza una serie de decisiones que hizo después de los 6 meses y reporta los resultados financieros un ...Starting at €5.74
-
Lyric Dinner Theater (A) (Spanish version)
Hamermesh, Richard G.; Sharpe, James M.Case HBS-815S16EntrepreneurshipMirando hacia atrás a los 5 años de pérdidas, Rivka Belzer, un MBA de nuevo cuño, pasos en su empresa familiar con su mandato de darle la vuelta o cerca de ella. En sus primeros 6 meses, se ha hecho una serie de cambios, con resultados mixtos, pero está empezando a mostrar un beneficio. Muchos estratégica, organización, comercialización, control y toma de decisiones operativas quedan por delante mientras se planea para el próximo año y trata de g...Starting at €8.20
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Case HBS-302S36Knowledge and CommunicationDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Starting at €8.20
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCase HBS-815114-EEntrepreneurshipIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Starting at €8.20
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCase HBS-813091-EEntrepreneurshipSupplement for case 809011Starting at €8.20
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCase HBS-810027-EEntrepreneurshipNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Starting at €8.20
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCase HBS-818068-EStrategyStarting at €8.20
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCase HBS-811089-EEntrepreneurshipIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Starting at €8.20